➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Harvard Business School
Mallinckrodt
Medtronic
Merck

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DELATESTRYL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Delatestryl

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01017458 Safety and Tolerability of MK0773 in Healthy Older Men (0773-004) Completed Merck Sharp & Dohme Corp. Phase 1 2007-06-01 This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK0773 in healthy older men.
NCT03516812 Testosterone Enanthate and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer Recruiting National Cancer Institute (NCI) Phase 2 2018-08-29 This phase II trial studies how well testosterone enanthate and olaparib work in treating participants with prostate cancer that has progressed despite hormonal therapy. Hormonal therapy, such as leuprolide, may lessen the amount of male sex hormones made by the body. In patients that have developed progressive cancer in spite of standard hormonal treatment (i.e. castration-resistant prostate cancer), administering testosterone enanthate may result in regression of tumors by causing DNA damage in cancer cells that have adapted to low testosterone conditions. Olaparib may stop the growth of tumor cells by blocking some of the enzymes involved in repairing DNA damage. Therefore, giving testosterone enanthate and olaparib together may work better in treating castration-resistant prostate cancer by generating DNA damage that the cancer cell is unable to repair.
NCT03516812 Testosterone Enanthate and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer Recruiting University of Washington Phase 2 2018-08-29 This phase II trial studies how well testosterone enanthate and olaparib work in treating participants with prostate cancer that has progressed despite hormonal therapy. Hormonal therapy, such as leuprolide, may lessen the amount of male sex hormones made by the body. In patients that have developed progressive cancer in spite of standard hormonal treatment (i.e. castration-resistant prostate cancer), administering testosterone enanthate may result in regression of tumors by causing DNA damage in cancer cells that have adapted to low testosterone conditions. Olaparib may stop the growth of tumor cells by blocking some of the enzymes involved in repairing DNA damage. Therefore, giving testosterone enanthate and olaparib together may work better in treating castration-resistant prostate cancer by generating DNA damage that the cancer cell is unable to repair.
NCT03716739 Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency Not yet recruiting National Institute on Aging (NIA) Phase 2 2019-01-01 The purpose of this phase II trial is to determine the efficacy and safety of testosterone replacement therapy (TRT) in improving the symptoms of androgen deficiency and health-related quality of life in men with prostate cancer who have undergone radical prostatectomy.
NCT03716739 Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency Not yet recruiting Shalendar Bhasin, MD Phase 2 2019-01-01 The purpose of this phase II trial is to determine the efficacy and safety of testosterone replacement therapy (TRT) in improving the symptoms of androgen deficiency and health-related quality of life in men with prostate cancer who have undergone radical prostatectomy.
NCT04026880 Testosterone Effects on Pelvic Floor Muscles Not yet recruiting Brigham and Women's Hospital Phase 3 2020-01-01 An proof-of-concept study to determine whether administration of testosterone enanthate weekly results in greater improvements in structural and functional characteristics of pelvic floor muscles and urodynamic parameters in postmenopausal women with urinary incontinence than that associated with placebo administration
NCT04363164 Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression Not yet recruiting United States Department of Defense Phase 2 2020-07-01 Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Delatestryl

Condition Name

Condition Name for Delatestryl
Intervention Trials
Genital Diseases, Male 1
Urinary Incontinence 1
Locomotion Disorder, Neurologic 1
Androgen Deficiency 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Delatestryl
Intervention Trials
Prostatic Neoplasms 3
Gait Disorders, Neurologic 1
Spinal Cord Diseases 1
Adenocarcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Delatestryl

Trials by Country

Trials by Country for Delatestryl
Location Trials
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Delatestryl
Location Trials
Maryland 1
Washington 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Delatestryl

Clinical Trial Phase

Clinical Trial Phase for Delatestryl
Clinical Trial Phase Trials
Phase 3 1
Phase 2 4
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Delatestryl
Clinical Trial Phase Trials
Not yet recruiting 4
Completed 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Delatestryl

Sponsor Name

Sponsor Name for Delatestryl
Sponsor Trials
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 1
Merck Sharp & Dohme Corp. 1
United States Department of Defense 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Delatestryl
Sponsor Trials
Other 8
NIH 2
Industry 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Moodys
Express Scripts
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.